Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics

Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics: Efficacy Study in Adults and Children. Randomized Prospective Study With Direct Individual Benefit

This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. It is an efficacy study in adults and children and a randomized prospective study.

Inclusion Criteria:

• Patients suffering from cancer of any type, at any stage, hospitalized at the Institut Gustave Roussy
• Aged from 6 to 14 years old (group A) and from 15 to 70 years old (adults)
• Presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to peritoneal carcinosis
• Pain resistant to morphinic treatment

Exclusion Criteria:

• Cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction (MI) of less than 3 months
• Neurological: non-controlled epilepsy, encephalopathy, or dementia
• Severe hepatic insufficiency
• Severe renal insufficiency
• Respiratory insufficiency
• Patients having surgery or in postoperative period
• Known deficit in G6PD, alanine exposure, or sulphamide treatment
• Porphyria
• Weight > 80 kg